|
시장보고서
상품코드
2126533
멀티플렉스 어세이 : 시장 인사이트, 경쟁 구도 및 시장 예측(2034년)Multiplex Assays - Market Insights, Competitive Landscape, and Market Forecast - 2034 |
||||||
DelveInsight
개요 :
- 멀티플렉스 분석 시장은 2025년에 41억 달러로 추정되며, 2034년까지 93억 달러에 달할 것으로 전망됩니다. 이러한 성장은 고처리량 및 다중 바이오마커 프로파일링의 급속한 보급, 감염병 검사에서 증후군별 분자 진단의 확대, 그리고 단백질체학 및 정밀 종양학에 대한 연구개발 투자 증가에 힘입은 것입니다.
- 전 세계 멀티플렉스 어세이 시장은 2026-2034년까지의 예측 기간 중 연평균 성장률(CAGR) 9.5%로 성장할 것으로 전망됩니다.
- 제품 유형별로는 2025년에 시약 및 소모품 부문이 66%의 점유율을 차지하며 멀티플렉스 분석 시장을 주도했습니다.
- 유형별로는 2025년에 단백질 멀티플렉스 분석 부문이 46%의 점유율을 차지하며 멀티플렉스 분석 시장을 촉진했습니다.
- 기술별로는 2025년에 멀티플렉스 면역 분석법 부문이 28%의 점유율을 차지하며 멀티플렉스 분석 시장을 주도했습니다.
- 용도별로는 2025년에 종양학 부문이 29%의 점유율을 차지하며 멀티플렉스 분석 시장을 촉진했습니다.
- 북미는 2025년에 40%의 점유율로 전 세계 멀티플렉스 분석 시장의 매출을 주도하며, 지역별로는 전 세계에서 가장 높은 시장 점유율을 차지했습니다.
멀티플렉스 분석법이란 단일 검체 내에서 단백질, 핵산, 사이토카인, 바이오마커 등 여러 분석 대상 물질을 동시에 검출·정량할 수 있는 분석 기술로, 기존의 ELISA와 같은 순차적인 단일 분석 대상 물질 검사를 대체하여 단일 고처리량 워크플로우를 실현하는 것입니다. 현대 생의학 연구 및 진단 분야에서는 단일 매개변수 분석보다 복잡한 생물학적 시그니처의 동시 프로파일링에 대한 수요가 점점 더 높아지고 있으며, 멀티플렉스 분석법은 제약 연구개발, 임상 진단 및 학술연구에서 필수적인 툴로 자리 잡고 있습니다. 이 시장은 제품 유형별(기기, 시약·소모품), 유형별(세포 기반, 단백질, 핵산, 기타 멀티플렉스 분석법), 기술별로는 멀티플렉스 실시간 PCR, 유세포분석법, 멀티플렉스 면역측정법, 마이크로어레이, 질량분석법, 기타 플랫폼으로 구성됩니다. 용도별로는 감염병 진단, 종양학, 동반 진단, 신약 개발, 바이오마커 발견 및 검증이 주요 분야입니다. 또한 최종사용자별로는 제약·바이오의약품 기업, 병원·임상검사실, 학술·연구소가 대상이 됩니다. 정밀 의학의 부상, 증후군 기반 감염병 검사의 확대, 그리고 단백질체학 및 유전체학 바이오마커 플랫폼에 대한 막대한 투자에 힘입어, 멀티플렉스 분석법은 현대의 진단 및 중개 연구를 지원하는 필수적인 기반이 되고 있습니다.
멀티플렉스 분석 시장의 주요 성장 촉진요인
- 비드 기반 멀티플렉스 플랫폼이 임상 및 상업 분야에서 빠르게 채택되면서 수요가 증가하고 있으며, Luminex사의 xMAP 기술은 10만 5,000건 이상의 동료 심사 논문에 인용되었고, 전 세계에서 2만 대 이상의 장비가 도입되었습니다.
- 감염병 검사를 위한 증후군 기반 다중 분자 진단의 확대가 도입을 가속화하고 있으며, QIAGEN사는 2025년 9월 고처리량형 ‘QIAstat-Dx Rise’ 시스템에 대해 FDA 승인을 획득했습니다. 이는 해당 기업에게 올해 세 번째로 획득한 ‘QIAstat-Dx’ 시리즈 승인이며, 100개국 이상에서 4,600대 이상의 도입 대수를 더욱 확대하고 있습니다.
- Seegene사의 독자적인 기술인 신드로믹 실시간 PCR 기술은 하나의 반응 튜브로 최대 14종의 병원체를 검출할 수 있으며, 100개국 이상에 3억 4,000만 건 이상의 COVID-19 검사 키트를 공급하는 기반이 되었습니다. 이후 이 기술은 HSV, VZV, mpox 바이러스 등 증상이 겹치는 병원체의 감별 진단 분야로도 적용 범위를 넓혀가고 있습니다.
- 단백질체학 및 바이오마커 발견을 위한 제약·바이오기술 분야의 연구개발 투자 증가에 따라 Bio-Techne사의 ‘Simple Plex Ella’ 시스템과 같은 자동 멀티플렉스 면역측정 플랫폼에 대한 수요가 확대되고 있습니다. 이 시스템은 350개 이상의 표적으로 구성된 측정 메뉴에서 시료 1개당 최대 8개의 분석 대상 물질을 90분 이내에 정량할 수 있습니다.
- 각 진단 기기 제조사들은 멀티플렉스 지원 제품 포트폴리오에서 지속적인 두 자릿수 성장을 보고하고 있습니다. Revvity의 진단 부문은 2025년 4분기 매출이 10% 증가했으며, 그중 7%가 유기적 성장이었기 때문에 면역 진단 및 멀티플렉스 검사 플랫폼에 대한 수요가 증가하고 있음을 지원하고 있습니다.
- 전략적 통합을 통해 밸류체인 전반에 걸쳐 멀티플렉스 기능이 확대되고 있습니다. 그 대표적인 사례로, DiaSorin사가 Luminex Corporation을 18억 달러에 인수한 것을 들 수 있습니다. 이 인수를 통해 DiaSorin사의 진단 사업과 Luminex사의 멀티플렉스 기술이 융합되어 생명과학 분야의 사업 범위가 확대되었습니다.
- 정밀 의학, 증후군 검사의 확대, 바이오마커 주도 신약 개발, 그리고 플랫폼 통합이 맞물려 2034년까지 멀티플렉스 분석 시장이 강력한 성장세를 이어갈 것으로 예상됩니다.
멀티플렉스 분석 시장의 성장에 기여하는 요인
시장 촉진요인
멀티플렉스 면역분석법 및 비드 기반 플랫폼의 채택 확대
멀티플렉스 분석 시장의 가장 확고한 촉진요인은 바이오마커 연구 전반에 걸친 비드 기반 및 미세유체식 멀티플렉스 면역 분석 플랫폼의 광범위한 채택입니다. Luminex사의 xMAP 기술과 같은 비드 기반 플랫폼 및 Bio-Rad사의 Bio-Plex Pro 포트폴리오, Bio-Techne사의 Simple Plex Ella 시스템과 같은 패널 기반 시스템을 통해 연구자들은 소량의 단일 샘플로부터 사이토카인, 케모카인,질환 바이오마커를 프로파일링할 수 있게 되어, 수많은 연속적인 ELISA 측정을 하나의 멀티플렉스 워크플로로 대체할 수 있습니다. Luminex xMAP 기술만 해도 10만 5,000건 이상의 동료 심사 연구 논문에서 인용되었으며, 전 세계에서 2만 대 이상의 장비가 도입된 점을 통해 학술기관, 제약 기업, 임상 검사실에서의 광범위한 도입 실태가 뚜렷이 드러나고 있습니다. 바이오마커 패널이 점점 더 복잡해지고, 검사실이 검체량을 줄이고 처리 시간을 단축하려는 가운데, 멀티플렉스 면역측정 플랫폼 및 관련 시약 메뉴에 대한 수요는 지속적으로 확대되고 있으며, 이는 2034년까지의 시장 성장 기반이 되고 있습니다.
증후군 기반 다중 분자 진단의 확대
감염병 검사를 위한 증후군 기반 다중 분자 진단의 급속한 성장은 시장 확대의 강력한 원동력이 되고 있습니다. QIAGEN사의 QIAstat-Dx 플랫폼이나 Seegene사의 Allplex 분석법과 같은 시스템은 중복되는 임상 증상을 유발하는 여러 병원체를 PCR 기반의 실시간 검사로 동시에 검출할 수 있게 하여, 진단 정확도를 향상시키는 동시에 불필요한 항생제 사용을 줄입니다. QIAGEN은 2025년 9월, 고처리량형 QIAstat-Dx Rise 시스템에 대해 FDA 승인을 획득했습니다. 이는 해당 연도에 QIAGEN사가 획득한 세 번째 QIAstat-Dx 제품 승인으로, 100개국 이상에 걸쳐 4,600대 이상의 도입 대수를 더욱 확대했습니다. 한편, 시겐의 증후군별 실시간 PCR 기술은 하나의 튜브로 최대 14유형의 병원체를 검출할 수 있으며, HSV, VZV, mpox 바이러스 등 증상이 겹치는 질환의 감별 진단에 활용되고 있습니다. 호흡기계, 소화기계 및 신종 감염증의 검사 건수가 증가함에 따라 병원 및 검사 기관에서 증후군별 멀티플렉스 패널이 단일 표적 분석법을 대체하는 경향이 강해지고 있습니다.
시장 제약 요인
성장세는 강하지만, 멀티플렉스 분석 시장은 중대한 제약에 직면해 있습니다. 멀티플렉스 측정 장비의 높은 초기 비용과 전용 시약 카트리지 및 패널에 드는 지속적인 비용은 소규모 검사실이나 가격에 민감한 시장에서 도입 장벽이 되고 있습니다. 동시에 측정되는 분석 대상의 수가 늘어날수록 교차 반응, 신호 간섭, 개별 표적에 대한 감도 저하의 위험이 높아지기 때문에 고도로 멀티플렉스화된 패널의 검증은 기술적으로 어려우며 신중한 분석법 설계와 엄격한 품질관리가 요구됩니다. 다중 진단 패널의 규제 승인 절차는 복잡합니다. 이는 새로운 병원체나 바이오마커 표적마다 일반적으로 개별적인 승인 또는 검증이 필요하므로 개발 기간이 길어지고 비용이 증가하기 때문입니다. 새로운 멀티플렉스 진단 패널의 보험 적용 및 도입 현황은 지역별로 여전히 편차가 있으며, 또한 멀티플렉스 분석법 개발, 바이오정보학, 데이터 해석에 대한 훈련을 받은 숙련된 인력 부족이 사업 규모 확대를 제약하고 있습니다. 또한 멀티플렉스 데이터세트의 복잡성이 심화됨에 따라 검사실의 정보 과학 및 데이터 관리 부담도 증가하고 있습니다. 이러한 비용, 기술, 규제, 인력에 관한 장벽이 복합적으로 작용하여 성장 속도를 둔화시키고 있습니다. 반면, 정밀 의학, 증후군 검사의 확대, 바이오마커 주도 신약 개발과 같은 근본적인 촉진요인들은 여전히 확고하게 자리 잡고 있습니다.
자주 묻는 질문
목차
제1장 멀티플렉스 어세이 시장 : 서론
제2장 멀티플렉스 어세이 시장 : 개요
제3장 멀티플렉스 어세이 시장 : 주요 요인 분석
제4장 AI, 지정학, 무역 및 경제의 동향
제5장 규제 분석
제6장 Porter's Five Forces 분석
제7장 멀티플렉스 어세이 시장 평가
제8장 멀티플렉스 어세이 시장 : 경쟁 구도
제9장 멀티플렉스 어세이 시장 : 스타트업 자금조달 및 투자 동향
제10장 멀티플렉스 어세이 시장 : 기업 개요 및 제품 개요
제11장 KOL의 견해
제12장 프로젝트 어프로치
제13장 DelveInsight 소개
제14장 면책사항 및 문의
KSAMultiplex Assays Market Summary
Overview:
- The Multiplex Assays market is estimated at USD 4.10 billion in 2025 and is projected to reach USD 9.30 billion by 2034. Growth is anchored in the rapid adoption of high-throughput, multi-analyte biomarker profiling, the expansion of syndromic molecular diagnostics for infectious disease testing, and rising R&D investment in proteomics and precision oncology.
- The global Multiplex Assays market is growing at a CAGR of 9.5% during the forecast period from 2026 to 2034.
- By product type, the reagents & consumables segment dominated the Multiplex Assays market with a 66% share in 2025.
- By type, the protein multiplex assays segment dominated the Multiplex Assays market with a 46% share in 2025.
- By technology, the multiplex immunoassays segment dominated the Multiplex Assays market with a 28% share in 2025.
- By application, the oncology segment dominated the Multiplex Assays market with a 29% share in 2025.
- North America dominated the global Multiplex Assays market revenue with a 40% share in 2025, representing the highest regional market share globally.
A multiplex assay is an analytical technique that enables the simultaneous detection and quantification of multiple analytes, such as proteins, nucleic acids, cytokines, and biomarkers, within a single sample, replacing sequential single-analyte tests such as conventional ELISA with a single, high-throughput workflow. Because modern biomedical research and diagnostics increasingly demand simultaneous profiling of complex biological signatures rather than single-parameter analysis, multiplex assays have become foundational tools across pharmaceutical R&D, clinical diagnostics, and academic research. The market is organized by product type across instruments and reagents & consumables; by type, spanning cell-based, protein, nucleic acid, and other multiplex assays; by technology, including multiplex real-time PCR, flow cytometry, multiplex immunoassays, microarray, mass spectrometry, and other platforms; by application, led by infectious disease diagnostics, oncology, companion diagnostics, drug discovery & development, and biomarker discovery & validation; and by end-user, spanning pharmaceutical and biopharmaceutical companies, hospitals and clinical laboratories, and academic and research institutes. Driven by the rise of precision medicine, the expansion of syndromic infectious disease testing, and heavy investment in proteomic and genomic biomarker platforms, multiplex assays have become essential infrastructure underpinning modern diagnostics and translational research.
Multiplex Assays Market Key Growth Drivers
- The rapid clinical and commercial adoption of bead-based multiplexing platforms is driving demand, with Luminex xMAP Technology cited in more than 105,000 peer-reviewed studies and supporting a worldwide installed base exceeding 20,000 instruments.
- The expansion of syndromic multiplex molecular diagnostics for infectious disease testing is accelerating adoption, with QIAGEN securing FDA clearance for its higher-throughput QIAstat-Dx Rise system in September 2025, its third QIAstat-Dx clearance of the year, extending an installed base of over 4,600 instruments across more than 100 countries.
- Seegene's proprietary syndromic real-time PCR technology, capable of detecting up to 14 pathogens in a single reaction tube, underpinned the supply of more than 340 million COVID-19 tests to over 100 countries and has since been extended to differential diagnosis of overlapping pathogens such as HSV, VZV, and mpox virus.
- Rising pharmaceutical and biotechnology R&D investment in proteomics and biomarker discovery is expanding demand for automated multiplex immunoassay platforms, such as Bio-Techne's Simple Plex Ella system, which quantifies up to eight analytes per sample in under 90 minutes across a menu of more than 350 targets.
- Diagnostics companies are reporting sustained double-digit growth in multiplex-enabled portfolios; Revvity's diagnostics segment posted 10% fourth-quarter revenue growth in 2025, with 7% organic growth, reinforcing demand for immunodiagnostic and multiplex testing platforms.
- Strategic consolidation is expanding multiplexing capability across the value chain, exemplified by DiaSorin's USD 1.8 billion acquisition of Luminex Corporation, which combined DiaSorin's diagnostics footprint with Luminex's multiplexing technology and expanded life-science reach.
- The convergence of precision medicine, syndromic testing expansion, biomarker-driven drug development, and platform consolidation is expected to sustain strong growth in the multiplex assays market through 2034.
Key Companies in Multiplex Assays Market
The competitive landscape is led by the following active manufacturers:
- Thermo Fisher Scientific, Inc.
- Bio-Rad Laboratories, Inc.
- DiaSorin S.p.A. (Luminex)
- QIAGEN N.V.
- Illumina, Inc.
- Merck KGaA
- Becton, Dickinson and Company (BD)
- Revvity, Inc.
- Bio-Techne Corporation
- Seegene Inc.
Factors Contributing to the Growth of the Multiplex Assays Market
Market Drivers
Expanding Adoption of Multiplex Immunoassay and Bead-Based Platforms
The most established driver of the Multiplex Assays market is the broad adoption of bead-based and microfluidic multiplex immunoassay platforms across biomarker research. Bead-based platforms such as Luminex xMAP Technology and panel-based systems such as Bio-Rad's Bio-Plex Pro portfolio and Bio-Techne's Simple Plex Ella system allow researchers to profile cytokines, chemokines, and disease biomarkers from a single low-volume sample, replacing many sequential ELISA runs with one multiplexed workflow. Luminex xMAP Technology alone has been cited in more than 105,000 peer-reviewed studies and supports a worldwide installed base exceeding 20,000 instruments, underscoring the depth of adoption across academic, pharmaceutical, and clinical laboratories. As biomarker panels grow in complexity and laboratories seek to conserve sample volume and turnaround time, demand for multiplex immunoassay platforms and their associated reagent menus continues to expand, anchoring market growth through 2034.
Expansion of Syndromic Multiplex Molecular Diagnostics
The rapid growth of syndromic, multiplex molecular diagnostics for infectious disease testing is a powerful driver of market expansion. Systems such as QIAGEN's QIAstat-Dx platform and Seegene's Allplex assays enable simultaneous, real-time PCR-based detection of multiple pathogens that cause overlapping clinical symptoms, improving diagnostic accuracy while reducing unnecessary antibiotic use. QIAGEN received FDA clearance for its higher-throughput QIAstat-Dx Rise system in September 2025, its third QIAstat-Dx clearance that year, extending an installed base of more than 4,600 instruments across over 100 countries, while Seegene's syndromic real-time PCR technology, capable of detecting up to 14 pathogens in a single tube, has been adapted to differentiate overlapping conditions such as HSV, VZV, and mpox virus. As respiratory, gastrointestinal, and emerging infectious disease testing volumes rise, syndromic multiplex panels are increasingly displacing single-target assays across hospital and reference laboratories.
Market Restraints
Despite strong momentum, the Multiplex Assays market faces material constraints. The high upfront cost of multiplexing instruments and the recurring cost of proprietary reagent cartridges and panels create adoption barriers for smaller laboratories and price-sensitive markets. Highly multiplexed panels can be technically challenging to validate, as increasing the number of simultaneously measured analytes raises the risk of cross-reactivity, signal interference, and reduced sensitivity for individual targets, requiring careful assay design and rigorous quality control. Regulatory pathways for multiplex diagnostic panels are complex, since each new pathogen or biomarker target typically requires separate clearance or validation, lengthening development timelines and raising costs. Reimbursement and adoption of newer multiplex diagnostic panels remain uneven across geographies, and the shortage of skilled personnel trained in multiplex assay development, bioinformatics, and data interpretation constrains scale-up. The growing complexity of multiplex datasets also raises the informatics and data-management burden on laboratories. Together, these cost, technical, regulatory, and workforce barriers temper the pace of growth, even as the underlying drivers of precision medicine, syndromic testing expansion, and biomarker-driven drug development remain firmly intact.
Multiplex Assays Market Segment Analysis
The multiplex assays market by product type (instruments, reagents & consumables), type (cell-based multiplex assays, protein multiplex assays, nucleic acid multiplex assays, others), technology (multiplex real-time pcr, flow cytometry, multiplex immunoassays, microarray, mass spectrometry, others), application (infectious disease diagnostics, oncology, companion diagnostics, drug discovery & development, biomarker discovery & validation, others), end-users (pharmaceutical & biopharmaceutical companies, hospitals & clinical laboratories, academic & research institutes, others), and geography (North America, Europe, Asia-Pacific, and Rest of World).
By Product Type
Dominant Subsegment: Reagents & Consumables.
The reagents & consumables segment accounted for 66% of the Multiplex Assays market in 2025. Reagents and consumables lead because every multiplex run consumes proprietary assay kits, cartridges, beads, and panels, creating a recurring, high-frequency revenue stream that compounds with the growing installed base of multiplex instruments, mirroring the razor-and-blade model that underpins platforms such as Bio-Rad's Bio-Plex Pro panels, Luminex xMAP kits, and Bio-Techne's Simple Plex cartridges. As laboratories expand the breadth of biomarker and pathogen panels they run and as syndromic testing volumes rise, consumable demand scales directly with usage rather than one-time capital purchases. Instruments remain essential as the enabling capital investment and are important for placing new multiplex platforms into laboratories, but the sheer frequency and volume of consumable purchases across research, clinical, and pharmaceutical settings secure the segment's clear leadership across the forecast period.
By Type
Dominant Subsegment: Protein Multiplex Assays.
The protein multiplex assays segment accounted for 46% of the Multiplex Assays market in 2025. Protein-based multiplex assays lead because cytokine, chemokine, and biomarker profiling remains the most established and widely adopted multiplexing application, supported by mature bead-based and microfluidic immunoassay platforms such as Luminex xMAP, Bio-Rad's Bio-Plex Pro portfolio, and Bio-Techne's Simple Plex Ella system, which together offer menus spanning hundreds of validated protein targets. The established analytical performance, broad target menus, and deep integration of protein multiplexing into immunology, oncology, and cardiovascular research sustain great and dependable demand. Nucleic acid multiplex assays are the fastest-growing type, propelled by the expansion of syndromic multiplex PCR testing for infectious disease, while cell-based multiplex assays are gaining traction in immune-monitoring and cell therapy quality control. Nonetheless, the breadth and maturity of the protein multiplexing ecosystem secure its leadership across the forecast period.
Multiplex Assays Market Region Analysis
Dominant Region: North America
North America accounted for 40% of the global Multiplex Assays market revenue in 2025, representing the highest regional market share globally. The region's dominance reflects a mature life-science research ecosystem, deep clinical-diagnostics infrastructure, and the concentration of leading multiplex platform providers, including Thermo Fisher Scientific, Bio-Rad Laboratories, Illumina, and Bio-Techne, headquartered in the United States. North America hosts the largest base of academic and pharmaceutical R&D spending on biomarker discovery and companion diagnostics, and sponsors benefit from clear FDA regulatory pathways that have supported a wave of syndromic multiplex diagnostic clearances, including QIAGEN's QIAstat-Dx family. The commercial strength of multiplex immunoassay and molecular diagnostic platforms, combined with a deep clinical-research pipeline and rising precision-oncology adoption, drives substantial demand across instruments and consumables. Strong reimbursement pathways, regulatory clarity, and proximity to leading platform developers anchor the region's continued leadership across the forecast period.
Fastest Growing Region: Asia-Pacific
Asia-Pacific is the fastest-growing region in the Multiplex Assays market. The region's elevated CAGR is driven by rapidly expanding biopharmaceutical R&D investment, growing genomics and proteomics research capacity, and rising healthcare infrastructure spending across China, Japan, India, South Korea, and Australia. China is scaling domestic molecular diagnostics manufacturing and biomarker research capacity, Japan is expanding precision oncology and companion diagnostics adoption, India is emerging as a lower-cost hub for clinical research and diagnostic testing, and South Korea benefits from strong domestic multiplex molecular diagnostics leadership through Seegene. Government healthcare investment, expanding infectious disease surveillance programs, and growing biomarker-driven drug development activity are accelerating adoption across the region. The combination of rising disease burden, infrastructure build-out, and expanding local manufacturing capability positions Asia-Pacific as the principal source of incremental growth over the forecast period.
Regional Commentary
North America
North America accounted for 40% of the global Multiplex Assays market revenue in 2025. The United States dominates on the strength of its life-science research infrastructure, deep clinical-diagnostics base, FDA regulatory clarity, and the concentration of leading multiplex platform developers, while sustained R&D investment in proteomics and precision oncology, and steady clearance of new syndromic diagnostic panels, reinforce its leadership.
Europe
Europe is a large and advanced regional market, supported by a strong diagnostics and life-science industrial base exemplified by DiaSorin in Italy, QIAGEN in Germany and the Netherlands, and Merck KGaA in Germany, alongside established EMA regulatory frameworks and collaborative academic research networks. Continued expansion of syndromic multiplex panel menus and growing biomarker research investment reinforce the region's role in supplying both diagnostic and research multiplex platforms across Germany, the United Kingdom, France, Italy, and Spain.
Asia-Pacific
Asia-Pacific is the fastest-growing region, propelled by expanding biopharmaceutical R&D investment, growing genomics and proteomics research capacity, and rising healthcare infrastructure spending across China, Japan, India, South Korea, and Australia. China's expanding domestic diagnostics manufacturing, Japan's precision oncology adoption, India's growing clinical research base, and South Korea's multiplex molecular diagnostics leadership through Seegene are accelerating regional market growth.
Rest of World
The Rest of World region, spanning Latin America, the Middle East, and Africa, is an emerging growth frontier. Expanding clinical laboratory and healthcare infrastructure, rising demand for infectious disease surveillance and precision diagnostics, and efforts to align regulatory frameworks with global standards are gradually broadening access, while international partnerships and technology transfer support the build-out of regional multiplex testing capacity.
Multiplex Assays Market Competitive Landscape
The Multiplex Assays market is classified as Moderately Consolidated. A group of integrated, multi-platform life-science and diagnostics leaders, including Thermo Fisher Scientific, Bio-Rad Laboratories, DiaSorin (Luminex), QIAGEN, Illumina, Merck KGaA, and Becton Dickinson and Company, anchor the top tier through broad instrument and reagent portfolios and global commercial reach, while specialized and fast-scaling providers such as Revvity, Bio-Techne, and Seegene compete through focused platform innovation, deep reagent menus, and regional molecular-diagnostics leadership, increasing competition in the fastest-growing syndromic and biomarker-profiling segments.
The competitive landscape can be evaluated across the following dimensions:
- Market concentration: Moderately consolidated, with integrated, multi-platform life-science and diagnostics leaders anchoring the top tier alongside a fast-growing field of specialized multiplex platform providers.
- Leading players: Thermo Fisher Scientific, Bio-Rad Laboratories, DiaSorin (Luminex), and QIAGEN anchor the top tier through broad instrument and reagent portfolios and global regulatory clearances.
- Geographic reach: Leaders operate global, regionally distributed commercial and manufacturing networks; QIAGEN's QIAstat-Dx platform alone is available in more than 100 countries with over 4,600 instruments placed worldwide.
- Product portfolio strength: Top players offer end-to-end multiplex solutions spanning instruments, reagent kits, software, and bioinformatics support across research and clinical applications.
- Technology access: Ownership of proprietary multiplexing chemistries and detection platforms, including xMAP bead-based technology and automated microfluidic immunoassay systems, is a decisive competitive advantage.
- Strategic partnerships: Collaborations with technology and publishing partners, such as Seegene's alliance with Microsoft and Springer Nature to expand global access to multiplex PCR testing, extend reach and accelerate innovation.
- M&A activity: Active consolidation, including DiaSorin's USD 1.8 billion acquisition of Luminex Corporation and Thermo Fisher's acquisition of Olink, has broadened multiplexing capability across the industry.
- Manufacturing capabilities: Automated cartridge and bead-based manufacturing, high-throughput reagent production, and quality-controlled antibody and probe development are key competitive moats.
- Innovation focus: AI-enabled assay design, expanding syndromic panel menus, automated microfluidic immunoassay platforms, and spatial and single-cell multiplexing represent the leading edge of innovation.
Multiplex Assays Market Recent Developmental Activities
In September 2025, QIAGEN N.V. received FDA clearance for QIAstat-Dx Rise, a higher-throughput version of its automated syndromic testing system capable of processing up to 160 samples per day. Strategic significance: Marks QIAGEN's third FDA clearance for the QIAstat-Dx family in 2025 and extends an installed base exceeding 4,600 instruments across more than 100 countries.
In 2025, QIAGEN N.V. expanded its QIAstat-Dx panel menu with additional respiratory and gastrointestinal offerings, building on six FDA-cleared panels across the QIAstat-Dx family over twelve months. Strategic significance: Broadens QIAGEN's syndromic testing menu and reinforces its position in multiplex molecular diagnostics.
Multiplex Assays Market Segmentation
Multiplex Assays Market by Product Type
- Instruments
- Reagents & Consumables
Multiplex Assays Market by Type
- Cell-Based Multiplex Assays
- Protein Multiplex Assays
- Nucleic Acid Multiplex Assays
- Others
Multiplex Assays Market by Technology
- Multiplex Real-Time PCR
- Flow Cytometry
- Multiplex Immunoassays
- Microarray
- Mass Spectrometry
- Others
Multiplex Assays Market by Application
- Infectious Disease Diagnostics
- Oncology
- Companion Diagnostics
- Drug Discovery & Development
- Biomarker Discovery & Validation
- Others
Multiplex Assays Market by End-Users
- Pharmaceutical & Biopharmaceutical Companies
- Hospitals & Clinical Laboratories
- Academic & Research Institutes
- Others
Multiplex Assays Market by Geography
- North America Multiplex Assays Market
- United States Multiplex Assays Market Size in USD million (2023-2034)
- Canada Multiplex Assays Market Size in USD million (2023-2034)
- Mexico Multiplex Assays Market Size in USD million (2023-2034)
- Europe Multiplex Assays Market
- Germany Multiplex Assays Market Size in USD million (2023-2034)
- United Kingdom Multiplex Assays Market Size in USD million (2023-2034)
- France Multiplex Assays Market Size in USD million (2023-2034)
- Italy Multiplex Assays Market Size in USD million (2023-2034)
- Spain Multiplex Assays Market Size in USD million (2023-2034)
- Rest of Europe Multiplex Assays Market Size in USD million (2023-2034)
- Asia-Pacific Multiplex Assays Market
- China Multiplex Assays Market Size in USD million (2023-2034)
- Japan Multiplex Assays Market Size in USD million (2023-2034)
- India Multiplex Assays Market Size in USD million (2023-2034)
- Australia Multiplex Assays Market Size in USD million (2023-2034)
- South Korea Multiplex Assays Market Size in USD million (2023-2034)
- Rest of Asia-Pacific Multiplex Assays Market Size in USD million (2023-2034)
- Rest of the World (RoW) Multiplex Assays Market
- Middle East Multiplex Assays Market Size in USD million (2023-2034)
- Africa Multiplex Assays Market Size in USD million (2023-2034)
- South America Multiplex Assays Market Size in USD million (2023-2034)
Key Takeaways from the Multiplex Assays Market Report Study
- Market size analysis for the current Multiplex Assays market size (2025), and market forecast for 9 years (2026 to 2034).
- Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures that happened over the last 3 years.
- Key companies dominating the global Multiplex Assays market.
- Various opportunities available for competitors in the Multiplex Assays market space.
- What are the top-performing segments in 2025? How will these segments perform in 2034?
- Which are the top-performing regions and countries in the current Multiplex Assays market scenario?
- Which are the regions and countries where companies should concentrate their opportunities for Multiplex Assays market growth in the future?
Target audience who can benefit from this Multiplex Assays market report study
- Multiplex Assays product providers
- Research organizations and consulting companies
- Multiplex Assays -related organizations, associations, forums, and other alliances
- Government and corporate offices
- Start-up companies, venture capitalists, and private equity firms
- Distributors and traders dealing in Multiplex Assays
- Various end-users who want to know more about the Multiplex Assays market and the latest technological developments in the Multiplex Assays market.
Frequently Asked Questions:
Q1. What is the growth rate of the Multiplex Assays market?
The Multiplex Assays market is projected to expand at a CAGR of 9.5% during the forecast period from 2026 to 2034.
Q2. What is the market size of the Multiplex Assays market?
The Multiplex Assays market is estimated at USD 4.10 billion in 2025 and is projected to reach USD 9.30 billion by 2034.
Q3. Which region dominates the Multiplex Assays market?
North America dominated the Multiplex Assays market with a 40% share of global revenue in 2025, supported by a mature life-science research ecosystem, deep clinical-diagnostics infrastructure, FDA regulatory clarity, and the concentration of leading multiplex platform providers. Asia-Pacific is the fastest-growing region over the forecast period.
Q4. What are the key drivers of the Multiplex Assays market?
The principal drivers are the expanding adoption of bead-based and immunoassay multiplexing platforms, exemplified by Luminex xMAP Technology's citation in more than 105,000 peer-reviewed studies; the rapid growth of syndromic multiplex molecular diagnostics for infectious disease testing, led by QIAGEN's QIAstat-Dx and Seegene's Allplex platforms; rising pharmaceutical investment in proteomics and precision-oncology biomarker discovery; and continued strategic consolidation among leading platform providers.
Q5. Who are the major players in the Multiplex Assays market?
The major players include Thermo Fisher Scientific, Inc., Bio-Rad Laboratories, Inc., DiaSorin S.p.A. (Luminex), QIAGEN N.V., Illumina, Inc., Merck KGaA, Becton, Dickinson and Company (BD), Revvity, Inc., Bio-Techne Corporation, and Seegene Inc., among other active providers profiled in the Competitive Landscape section, along with Quanterix Corporation, Standard BioTools (Akoya Biosciences), and Meso Scale Diagnostics, LLC. Thermo Fisher Scientific, Bio-Rad Laboratories, DiaSorin, and QIAGEN lead through broad platform portfolios and global regulatory reach.
Table of Contents
1. Multiplex Assays Market Report Introduction
- 1.1 Scope of the Study
- 1.2 Market Segmentation
- 1.3 Market Assumptions
2. Multiplex Assays Market Executive Summary
- 2.1 Market at a Glance
3. Multiplex Assays Market Key Factors Analysis
- 3.1 Multiplex Assays Market Drivers
- 3.1.1 Expansion of Multiplex Immunoassay and Bead-Based Platforms
- 3.1.2 Expansion of Syndromic Multiplex Molecular Diagnostics
- 3.1.3 Rising Investment in Proteomics and Precision Oncology
- 3.1.4 Strategic Consolidation and Platform Integration
- 3.2 Multiplex Assays Market Restraints and Challenges
- 3.2.1 High Instrument and Recurring Reagent Costs
- 3.2.2 Technical Complexity and Cross-Reactivity in High-Plex Panels
- 3.2.3 Regulatory, Workforce, and Data-Management Complexity
- 3.3 Multiplex Assays Market Opportunities
- 3.3.1 AI-Enabled Assay Design and Automation
- 3.3.2 Emerging-Market and Point-of-Need Testing Expansion
4. Impact Analysis: AI, Geopolitical, Trade, and Economic Developments
5. Regulatory Analysis
- 5.1 United States
- 5.2 Europe
- 5.3 Japan
- 5.4 China
6. Multiplex Assays Market Porter's Five Forces Analysis
- 6.1 Bargaining Power of Suppliers
- 6.2 Bargaining Power of Buyers
- 6.3 Threat of New Entrants
- 6.4 Threat of Substitutes
- 6.5 Competitive Rivalry
7. Multiplex Assays Market Assessment
- 7.1 By Product Type
- 7.1.1 Instruments
- 7.1.2 Reagents & Consumables
- 7.2 By Type
- 7.2.1 Cell-Based Multiplex Assays
- 7.2.2 Protein Multiplex Assays
- 7.2.3 Nucleic Acid Multiplex Assays
- 7.2.4 Others
- 7.3 By Technology
- 7.3.1 Multiplex Real-Time PCR
- 7.3.2 Flow Cytometry
- 7.3.3 Multiplex Immunoassays
- 7.3.4 Microarray
- 7.3.5 Mass Spectrometry
- 7.3.6 Others
- 7.4 By Application
- 7.4.1 Infectious Disease Diagnostics
- 7.4.2 Oncology
- 7.4.3 Companion Diagnostics
- 7.4.4 Drug Discovery & Development
- 7.4.5 Biomarker Discovery & Validation
- 7.4.6 Others
- 7.5 By End-Users
- 7.5.1 Pharmaceutical & Biopharmaceutical Companies
- 7.5.2 Hospitals & Clinical Laboratories
- 7.5.3 Academic & Research Institutes
- 7.5.4 Others
- 7.6 By Geography
- 7.6.1 North America
- 7.6.1.1 United States Multiplex Assays Market Size in USD million (2023-2034)
- 7.6.1.2 Canada Multiplex Assays Market Size in USD million (2023-2034)
- 7.6.1.3 Mexico Multiplex Assays Market Size in USD million (2023-2034)
- 7.6.2 Europe
- 7.6.2.1 Germany Multiplex Assays Market Size in USD million (2023-2034)
- 7.6.2.2 United Kingdom Multiplex Assays Market Size in USD million (2023-2034)
- 7.6.2.3 France Multiplex Assays Market Size in USD million (2023-2034)
- 7.6.2.4 Italy Multiplex Assays Market Size in USD million (2023-2034)
- 7.6.2.5 Spain Multiplex Assays Market Size in USD million (2023-2034)
- 7.6.2.6 Rest of Europe Multiplex Assays Market Size in USD million (2023-2034)
- 7.6.3 Asia-Pacific
- 7.6.3.1 China Multiplex Assays Market Size in USD million (2023-2034)
- 7.6.3.2 Japan Multiplex Assays Market Size in USD million (2023-2034)
- 7.6.3.3 India Multiplex Assays Market Size in USD million (2023-2034)
- 7.6.3.4 Australia Multiplex Assays Market Size in USD million (2023-2034)
- 7.6.3.5 South Korea Multiplex Assays Market Size in USD million (2023-2034)
- 7.6.3.6 Rest of Asia-Pacific Multiplex Assays Market Size in USD million (2023-2034)
- 7.6.4 Rest of World
- 7.6.4.1 Middle East Multiplex Assays Market Size in USD million (2023-2034)
- 7.6.4.2 Africa Multiplex Assays Market Size in USD million (2023-2034)
- 7.6.4.3 South America Multiplex Assays Market Size in USD million (2023-2034)
- 7.6.1 North America
8. Multiplex Assays Market Competitive Landscape
- 8.1 Market Concentration and Structure
- 8.2 Competitive Positioning and Market Share Analysis (Premium Offering)
9. Multiplex Assays Market Startup Funding and Investment Trends
10. Multiplex Assays Market Company and Product Profiles
- 10.1 Thermo Fisher Scientific, Inc.
- 10.1.1 Company Overview
- 10.1.2 Company Snapshot
- 10.1.3 Financial Overview
- 10.1.4 Service Portfolio
- 10.1.5 Strategic Initiatives / Entropy
- 10.2 Bio-Rad Laboratories, Inc.
- 10.2.1 Company Overview
- 10.2.2 Company Snapshot
- 10.2.3 Financial Overview
- 10.2.4 Product Portfolio
- 10.2.5 Strategic Initiatives / Entropy
- 10.3 DiaSorin S.p.A. (Luminex)
- 10.3.1 Company Overview
- 10.3.2 Company Snapshot
- 10.3.3 Financial Overview
- 10.3.4 Product Portfolio
- 10.3.5 Strategic Initiatives / Entropy
- 10.4 QIAGEN N.V.
- 10.4.1 Company Overview
- 10.4.2 Company Snapshot
- 10.4.3 Financial Overview
- 10.4.4 Product Portfolio
- 10.4.5 Strategic Initiatives / Entropy
- 10.5 Illumina, Inc.
- 10.5.1 Company Overview
- 10.5.2 Company Snapshot
- 10.5.3 Financial Overview
- 10.5.4 Product Portfolio
- 10.5.5 Strategic Initiatives / Entropy
- 10.6 Merck KGaA
- 10.6.1 Company Overview
- 10.6.2 Company Snapshot
- 10.6.3 Financial Overview
- 10.6.4 Product Portfolio
- 10.6.5 Strategic Initiatives / Entropy
- 10.7 Becton, Dickinson and Company (BD)
- 10.7.1 Company Overview
- 10.7.2 Company Snapshot
- 10.7.3 Financial Overview
- 10.7.4 Product Portfolio
- 10.7.5 Strategic Initiatives / Entropy
- 10.8 Revvity, Inc.
- 10.8.1 Company Overview
- 10.8.2 Company Snapshot
- 10.8.3 Financial Overview
- 10.8.4 Product Portfolio
- 10.8.5 Strategic Initiatives / Entropy
- 10.9 Bio-Techne Corporation
- 10.9.1 Company Overview
- 10.9.2 Company Snapshot
- 10.9.3 Financial Overview
- 10.9.4 Product Portfolio
- 10.9.5 Strategic Initiatives / Entropy
- 10.10 Seegene Inc.
- 10.10.1 Company Overview
- 10.10.2 Company Snapshot
- 10.10.3 Financial Overview
- 10.10.4 Product Portfolio
- 10.10.5 Strategic Initiatives / Entropy
For illustrative purposes, only the top 10 companies are listed in the Table of Contents. The report may include analysis and references to additional companies where relevant to the market assessment.
